Clinical Updates in
NON–SMALL CELL LUNG CANCER

New Management Strategies to Improve Patient Outcomes

Guidelines

NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (version 4), 2015

NCCN Guidelines Patients: Non-Small Cell Lung Cancer (version 1), 2014
National Comprehensive Cancer Network, patient and caregiver resources.
  - http://www.nccn.org/patients/guidelines/nscl/index.html#10

Other Resources

Lung Cancer Alliance
Founded in 1995, Lung Cancer Alliance is the oldest and leading nonprofit organization dedicated to saving lives and advancing research by empowering those living with and at risk for lung cancer.
  - http://www.lungcanceralliance.org/

American Cancer Society
For over 100 years, the American Cancer Society has worked relentlessly to save lives and create a world with less cancer. Together with millions of our supporters worldwide, we help people stay well and get well, find cures, and fight back against cancer.
  - http://www.cancer.org/

National Cancer Institute
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients.
  - www.cancer.gov
Update on immune checkpoint inhibitors in lung cancer.

Immune checkpoint inhibitors in clinical trials.

Review of the current targeted therapies for non-small-cell lung cancer.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

A phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC).

Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): An Update of ASCEND-1.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC).
▶ http://annonc.oxfordjournals.org/content/25/suppl_4/iv149.2.abstract

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

The blockade of immune checkpoints in cancer immunotherapy.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.